The clinical study of the safety and efficacy of denosumab for glucocorticoid-induced osteoporosis

The clinical study of the safety and efficacy of denosumab for glucocorticoid-induced osteoporosis - The clinical study of the safety and efficacy of denosumab for glucocorticoid-induced osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015180

Enrollment

Registered

2015-11-01

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucocorticoid-induced osteoporosis

Interventions

SC denosumab 60mg every 6 months for 2 years

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who took gulcocorticoid (the gulcocorticoid dose was not less than 1mg/day and not more than 10mg/day prednisone or equivalent last 6 months) for over 12 months 2.Patients who took bisphosphonate or teriparatide or activated vitamin D for over 12 months 3.Patients who didn't improvement in bone mineral density compared with 6 months ago 4.Patients who scored >3 in the literature "Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research"

Exclusion criteria

Exclusion criteria: Patients with hypocalcemia

Design outcomes

Primary

Measure	Time frame
The change of bone mineral density after 6 months, 12 months, 18 months,and 24 months	—

Secondary

Measure	Time frame
The change of bone metabolism marker (BAP and TRACP-5b) after 3 months, 6 months, 12 months, 18 months,and 24 months	—

Countries

Japan

Contacts

Public ContactTakaaki ishida

Osaka Medical College Department of Internal Medicine (I)

in1342@osaka-med.ac.jp+81-72-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026